NEW YORK – Thermo Fisher Scientific said on Tuesday that it received CE-IVD marking for the Ion Torrent Genexus Dx Integrated Sequencer this month and is making the platform commercially available for diagnostic testing and clinical research.
"With the automated, easy-to-use Genexus Dx Integrated Sequencer, any hospital — including regional and community hospitals — can bring [next-generation sequencing] in house, giving clinicians access to timely, comprehensive genomic profiling results," said Garret Hampton, president of clinical NGS and oncology at Thermo Fisher, in a statement.
The company said it is also developing a sample-to-report diagnostic workflow and a portfolio of clinically validated assays for the Genexus, including comprehensive genomic profiling and hemato-oncology assays.
Thermo Fisher has been offering the research-use-only version of the Ion Torrent Genexus since its launch in late 2019.